Skip to content

Ivan Skorodumov

4 papers in the library · 99 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC

Research Square March 31, 2026 Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al.

Abstract Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experiences, but progress has been limited by a lack of experimental models that capture these context-dependent...

A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May 1, 2025 Marcus W. Meinhardt, Ivan Skorodumov, Jérôme Jeanblanc et al. 8 citations

The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol...

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats

Translational Psychiatry December 14, 2023 Ivan Skorodumov, Rainer Spanagel, Jonathan R Reinwald et al. 25 citations

Abstract Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin’s general mode of action and (2) AUD-specific alterations of responsivity to psilocybin treatment in...

Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse

Neuropsychopharmacology May 5, 2020 Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al. 66 citations

For most psychiatric disorders, including alcohol use disorder (AUD), approved pharmacological treatments are limited in their effectiveness, and new drugs that can easily be translated into the clinic are needed. Currently, great hope lies in the potential of psychedelics to effectively treat AUD. The primary hypothesis is that a single session of psychedelic-guided psychotherapy can restore...